The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat
Open accessAbstract
The biochemical and behavioral effects of a nonpeptidic, selective, and brain-penetrant agonist at the ORL1 receptor are reported herein. This low molecular weight compound {(1 S ,3a S )-8- (2,3,3a,4,5,6-hexahydro-1 H -phenalen-1-yl)-1-phenyl-1,3,8-triaza- spiro[4.5]decan-4-one} has high affinity for recombinant human ORL1 receptors and has 100-fold selectivity for ORL1 over other members of the opioid receptor family. It is a full agonist at these receptors and elicits dose-dependent anxiolytic-like effects in a set of validated models of distinct types of anxiety states in the rat (i.e., elevated plus-maze, fear-potentiated startle, and operant conflict). When given systemically, the compound has an efficacy and potency comparable to those of a benzodiazepine anxiolytic such as alprazolam or diazepam. However, this compound is differentiated from a classical benzodiazepine anxiolytic by a lack of efficient anti-panic-like activity, absence of anticonvulsant properties, and lack of effects on motor performance and cognitive function at anxiolytic doses (0.3 to 3 mg/kg i.p.). No significant change in intracranial self-stimulation performance and pain reactivity was observed in this dose range. Higher doses of this compound (≥10 mg/kg) induced disruption in rat behavior. These data confirm the notable anxiolytic-like effects observed at low doses with the orphanin FQ/nociceptin neuropeptide given locally into the brain and support a role for orphanin FQ/nociceptin in adaptive behavioral fear responses to stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor
Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., et al. (1995) · Nature · doi:10.1038/377532a0 · Cited by 1,912
Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor
Reinscheid, R. K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., & Civelli, O. (1995) · Science · doi:10.1126/science.270.5237.792 · Cited by 1,821
ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization
Mollereau, C., Parmentier, M., Mailleux, P., Butour, J.-L., Moisand, C., Chalon, P., Caput, D., Vassart, G., & Meunier, J.-C. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80235-1 · Cited by 1,077
Geller, I., & Seifter, J. (1960) · Psychopharmacologia · doi:10.1007/bf00429273 · Cited by 780
Fear-potentiated startle: A neural and pharmacological analysis
Davis, M., Falls, W. A., Campeau, S., & Kim, M. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90102-v · Cited by 748
Bunzow, J. R., Saez, C., Mortrud, M., Bouvier, C., Williams, J. T., Low, M., & Grandy, D. K. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00561-3 · Cited by 607
Orphanin FQ is a functional anti-opioid peptide
Mogil, J. S., Grisel, J. E., Reinscheid, R. K., Civelli, O., Belknap, J. K., & Grandy, D. K. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00338-7 · Cited by 375
Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress
Jenck, F., Moreau, J.-L., Martin, J. R., Kilpatrick, G. J., Reinscheid, R. K., Monsma, F. J., Nothacker, H.-P., & Civelli, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14854 · Cited by 347
Self-citation5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential
Martin, J. R., Bös, M., Jenck, F., Moreau, J.-L., Mutel, V., Sleight, A. J., Wichmann, J., Andrews, J. S., Berendsen, H. H. G., Broekkamp, C. L. E., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37669-4 · Cited by 334
Self-citationOrphanin FQ/nociceptin: a role in pain and analgesia, but so much more
Darland, T., Heinricher, M. M., & Grandy, D. K. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01204-6 · Cited by 308
Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro
Connor, M., Vaughan, C. W., Chieng, B., & Christie, M. J. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb16080.x · Cited by 225
Jenck, F., Moreau, J.-L., & Martin, J. R. (1995) · Psychiatry Research · doi:10.1016/0165-1781(95)02673-k · Cited by 206
Self-citationVaughan, C. W., Ingram, S. L., & Christie, M. J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-03-00996.1997 · Cited by 174
The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion
Devine, D. P., Reinscheid, R. K., Monsma, F. J., Civelli, O., & Akil, H. (1996) · Brain Research · doi:10.1016/0006-8993(96)00476-3 · Cited by 145
Chronic mild stress-induced anhedonia model of depression
Moreau, J. ‐., Scherschlicht, R., Jenck, F., & Martin, J. R. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199511000-00003 · Cited by 144
Self-citationSchulz, S., Schreff, M., Nü, D., Gramsch, C., & Höllt, V. (1996) · Neuroreport · doi:10.1097/00001756-199611250-00045 · Cited by 130
Orphanin FQ, a novel neuropeptide with anti-stress-like activity
Griebel, G., Perrault, G., & Sanger, D. J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01684-4 · Cited by 100
Postsynaptic Mechanisms Underlying Responsiveness of Amygdaloid Neurons to Nociceptin/Orphanin FQ
Meis, S., & Pape, H.-C. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08133.1998 · Cited by 79
Pan, Y., Xu, J., Wan, B., Zuckerman, A., & Pasternak, G. W. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01039-4 · Cited by 58
Martin, J. R., Schoch, P., Jenck, F., Moreau, J., & Haefely, W. E. (1993) · Psychopharmacology · doi:10.1007/bf02253530 · Cited by 54
Self-citationFlorin, S., Leroux‐Nicollet, I., Meunier, J., & Costentin, J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00470-9 · Cited by 52
Nociceptin fails to affect heroin self-administration in the rat
Walker, J. R., Spina, M. G., Terenius, L. Y., & Koob, G. F. (1998) · Neuroreport · doi:10.1097/00001756-199807130-00017 · Cited by 44
Kyuhou, S.-I., & Gemba, H. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00956-2 · Cited by 24
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family
Mogil, J. S., & Pasternak, G. W. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01502-3 · Cited by 441
The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential
Lambert, D. G. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2572 · Cited by 357
Toll, L., Bruchas, M. R., Calo', G., Cox, B. M., & Zaveri, N. T. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.009209 · Cited by 297
Metadata
- Authors
- Jenck, F., Wichmann, J., Dautzenberg, F. M., Moreau, J.-L., Ouagazzal, A. M., Martin, J. R., Lundstrom, K., Cesura, A. M., Poli, S. M., Roever, S., Kolczewski, S., Adam, G., & Kilpatrick, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-04-11
- Volume
- 97
- Issue
- 9
- Pages
- 4938-4943
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2064420586
- Cited by
- 275
- References
- 24
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.